BiotechTube

ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + Capecitabine

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Ductal Adenocarcinoma

Conditions

Pancreatic Ductal Adenocarcinoma

Trial Timeline

Oct 16, 2025 → Jan 31, 2028

NCT ID
NCT07024615

About ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + Capecitabine

ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + Capecitabine is a phase 1 stage product being developed by Astellas Pharma for Pancreatic Ductal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07024615. Target conditions include Pancreatic Ductal Adenocarcinoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07024615Phase 1Recruiting

Competing Products

20 competing products in Pancreatic Ductal Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
pemetrexedEli LillyPhase 2
52
mFOLFIRINOX + RamucirumabEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
enzastaurin + gemcitabineEli LillyPhase 2
52
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
33
RamucirumabEli LillyPhase 1/2
41
GEMZAR + ALIMTAEli LillyPhase 3
77
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
52
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
33
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
33
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
52
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
77
Enzalutamide + Gemcitabine + Nab-paclitaxelAstellas PharmaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85